Journal
CURRENT PHARMACEUTICAL BIOTECHNOLOGY
Volume 24, Issue 10, Pages 1307-1314Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1389201024666221028092342
Keywords
Addiction; reward deficiency syndrome; dopamine; serotonin; ADHD; drug abuse
Ask authors/readers for more resources
This study found that chronic co-administration of methylphenidate (MP) and fluoxetine (FLX) can significantly reduce depressive and anxiety-like behaviors, as well as increase overall activity levels. These results provide important insights into the potential neurobiological and neurochemical effects of simultaneously using these two drugs.
Background Attention Deficit Hyperactivity Disorder (ADHD) can be comorbid with depression, often leading to the prescription of both methylphenidate (MP) and selective serotonin reuptake inhibitor (SSRI) antidepressants, such as fluoxetine (FLX). Moreover, these drugs are often misused as cognitive enhancers. This study examined the effects of chronic oral co-administration of MP and FLX on depressive- and anxiety-like behaviors. Methods Adolescent rats received daily either water (control), MP, FLX, or the combination of MP plus FLX in their drinking water over the course of 4 weeks. Results Data analysis shows a decrease in food consumption and body weight for rats exposed to FLX or the combination of MP and FLX. Sucrose consumption was significantly greater in FLX or MP+FLX groups compared to controls. FLX-treated rats showed no effect in the elevated plus maze (EPM; open arm time) and forced swim test (FST; latency to immobility). However, rats treated with the combination (MP+FLX) showed significant anxiolytic-like and anti-depressive-like behaviors (as measured by EPM and FST), as well as significant increases in overall activity (distance traveled in open field test). Finally, the combined MP+FLX treatment induced a decrease in anxiety and depressive-like behaviors significantly greater than the response from either of these drugs alone. Conclusion These behavioral results characterize the long-term effects of these drugs (orally administered) that are widely co-administered and co-misused and provide important insight into the potential neurobiological and neurochemical effects. Future research will determine the potential risks of the long-term use of MP and FLX together.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available